肌酸酐測量市場 - 預測 2024-2029

預計 2022 年肌酸酐測量市值為 2.9449 億美元，預測期內複合年成長率為 9.38%。

肌酸酐測量是為了檢查人體內腎臟的功能。殘留在人體內的化合物稱為肌酸酐。透過測量人體內的肌酸酐濃度可以判斷腎臟的狀況。肌酸酐水平可以從血液和尿液樣本中測量。過濾後的肌酸酐會作為尿液中的過濾廢物從體內排放。

肌酸酐測量市場的促進因素

影響肌酸酐測量市場成長的主要因素是腎臟疾病和其他影響腎功能的慢性疾病的盛行率不斷增加。實施適當的政府舉措和增加預防性醫療保健的採用也是推動肌酸酐測量市場的其他舉措。此外，老年人口的增加以及各種產品的開拓也是將進一步推動肌酸酐測量市場的因素。

腎臟相關疾病的盛行率增加

由於糖尿病和慢性腎臟病（CKD）盛行率的上升、人口老化以及研發力度的加大，全球肌酸酐測量市場預計在未來幾年將成長。全球肌酸酐測量產業也受到外源標記成分的開發、政府融資的增加和臨床實驗室業務的增加的推動。血清肌酸酐檢測在世界各地的臨床化學實驗室進行。市場供應商提供的有利報銷政策和尖端設計，例如閉塞袖帶和帶有植入連接的泵，預計也將促進肌酸酐測量市場的成長。

增加照護現場肌酸酐測量設備的使用

照護現場肌酸酐測定儀用於透過篩檢計畫早期診斷慢性腎臟病。使用可攜式設備進行肌酸酐照護現場分析可在居家醫療環境中提供快速診斷結果。這對於需要腎臟替代的末期腎功能衰竭病例也有益。透過 POC 進行居家肌酸酐檢測，由於其簡單和方便，可以進行更多的腎功能分析。

肌酸酐檢測技術進展

我們使用單模光纖-多芯光纖-多模光纖-單模光纖（SMFMCF-MMF-SMF）構建了一種簡單、攜帶式、高靈敏度的生物感測器，用於檢測人體內的肌酸酐。使用化學蝕刻將感測器探頭的直徑減小至 90 m (EW)，從而能夠產生強大的倏逝波。此感測器探針使用氧化石墨烯 (GO)、金奈米顆粒 (AuNP)、二硫化鉬奈米顆粒 (MoS2-NP) 和肌酸酐酶 (CA) 進行功能化。使用光纖局域表面等離子體共振 (LSPR) 測量肌酸酐濃度。2D (2D) 材料（GO 和 MoS2-NP）已用於增強生物相容性。此外，CA用於增加探針的特異性，EW用於提高AuNPs的LSPR效果。

對肌酸酐測量套件和試劑的需求不斷成長

影響腎功能的各種慢性疾病的日益普及也增加了對肌酸酐測量套件和試劑的需求。例如，腎衰竭最常見的原因分別是糖尿病和高血壓。全球易患腎臟疾病的老年人口不斷增加、旨在促進腎臟健康的有利政府立法以及開拓的監測技術正在促進肌酸酐測量市場的成長。採用照護現場肌酸酐測量設備作為一種快速方法就是這樣一個潛在的技術發展。

擴大酶法的採用

酵素法使用一種稱為肌酸酐磷酸激酶 (CPK) 的酵素將肌酸酐轉化為磷酸肌酸。然後使用磷酸肌酸測量來確定肌酸酐濃度。酵素法可用於血清、血漿和全血，並且比 Jaffe 的動力學方法更快。此外，觀察到約 30 mg/dL 至 700 mg/dL 的線性動態範圍。酵素法的主要缺點是容易受到尿液檢體中過量膽紅素、抗壞血酸和固色劑濃度的干擾。

血清肌酸酐預計將佔據最大市場佔有率

腎功能檢查中最常用的檢查項目之一是血清肌酸酐。它用於計算估計腎小球過濾率（eGFR），作為腎功能的指標。它是識別慢性腎臟疾病的絕佳指標。腎絲球濾過率（GFR）是腎功能的理想指標，與血中肌酸酐水平呈負相關。由於監測 GFR 非常耗時，因此通常使用考慮了血清肌酸酐 (sCr) 等內源性濾過指標的公式來估算 GFR。

血清肌酸酐檢測的不斷推出和進步、研發活動的擴大、知名公司採取重大戰略舉措、慢性腎臟病率上升等正在推動肌酸酐測量市場的成長。

北美的胚胎著床前基因檢測市場預計將穩定成長。

由於腎臟疾病盛行率上升、醫療基礎設施發達、預防性醫療意識不斷提高以及該地區對檢測的接受程度等多種原因，預計肌酸酐測量市場將在預測期內成長。例如，美國國家糖尿病、消化和腎臟疾病研究所估計，美國有 3700 萬人（近七分之一）患有慢性腎臟病(CKD)。患有糖尿病和高血壓（腎臟疾病的兩個主要原因）的美國人患慢性腎病的可能性明顯更高。

目錄

第1章簡介

• 市場概況
• 市場定義
• 調查範圍
• 市場區隔
• 貨幣
• 先決條件
• 基準年和預測年時間表

第2章調查方法

• 調查資料
• 先決條件

第3章執行摘要

• 研究亮點

第4章市場動態

• 市場促進因素
• 市場限制因素
• 波特五力分析
• 產業價值鏈分析

第5章肌酸酐測量市場：依類型

• 介紹
• 賈菲法
• 酵素法

第6章肌酸酐測量市場：依樣本類型

• 介紹
• 血液/血清
• 尿

第 7 章 肌酸酐測量市場：依最終用戶分類

• 介紹
• 醫院
• 診斷實驗室

第8章肌酸酐測量市場：按地區

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 其他
• 中東/非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 其他
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 印尼
  • 泰國
  • 其他

第9章競爭環境及分析

• 主要企業及策略分析
• 市場佔有率分析
• 合併、收購、協議和合作
• 供應商競爭力矩陣

第10章 公司簡介

• Mayo Clinic
• Ilex Medical
• Biogenix Inc. Pvt. Ltd.
• Nova Biomedical
• Sigma-Aldrich
• Cayman Chemical
• Biotec Co.
• Fresenius Kidney Care
• Fujifilm
• Healio

The creatinine measurement market was valued at US$294.49 million in 2022 and is expected to grow at a CAGR of 9.38% during the forecast period.

The creatinine measurement is performed to check the function of the kidney in the human body. The leftover chemical compound found in the human body is called creatinine. The status of the kidney can be figured out by measuring creatinine levels in the human body. The creatinine levels can be measured from blood samples and urine samples. After the process, the filtered-out creatinine exits the human body with urine as filtered waste.

Driving factors for the creatinine measurement market

The major factor influencing the growth of the creatinine measurement market is the growing prevalence of renal disorders and other chronic illnesses that affect renal function. Implementation of suitable government initiatives and increasing adoption of preventive healthcare are other initiatives that fuel the creatinine measurement market. Moreover, the increase in the geriatric population and various product developments are some other factors that further propel the creatinine measurement market.

Growing prevalence of kidney-related disease

The worldwide creatinine measurement market is anticipated to rise over the next years as a result of rising rates of diabetes and chronic kidney disease (CKD), an aging population, and increased R&D efforts. The global creatinine measurement industry is also being driven by the development of exogenous marker components, a rise in government financing, and an increase in clinical laboratory operations. Serum creatinine tests are carried out by clinical chemistry labs all over the world. Favourable reimbursement policies and cutting-edge designs created by market vendors, including occlusive cuffs or pumps with implant connections, are also anticipated to fuel this creatinine measurement market growth.

Increasing use of point-of-care creatinine instruments

Point-of-care creatinine instruments are used for early diagnosis of chronic kidney diseases throughout the screening programs. The use of portable devices for creatinine point-of-care analysis enables fast diagnostic results in homecare settings. This also proves to be beneficial for end-stage renal failure cases which require renal replacement. The use of home creatinine testing with POC leads to more renal function analysis owing to simplicity and convenience.

Technological advancement in the detection of creatinine

A straightforward, transportable, and sensitive biosensor is constructed using single-mode fiber-multicore fiber-multimode fiber-single mode fiber (SMFMCF-MMF-SMF) to detect creatinine in the human body. Chemical etching was used to shrink the sensing probe's diameter to 90 m (EWs), which allowed for the generation of powerful evanescent waves. The sensor probe is functionalized using graphene oxide (GO), gold nanoparticles (AuNPs), molybdenum disulfide nanoparticles (MoS2-NPs), and the enzyme creatininase (CA). Creatinine concentration is measured using fiber optic localized surface plasmon resonance (LSPR). To boost biocompatibility, two-dimensional (2D) materials (GO and MoS2-NPs) are used. CA is also used to increase probe specificity, while EWs are used to improve the LSPR effect of AuNPs.

Rising demand for creatinine measurement kits and reagents

A growth in the prevalence of various chronic diseases that affect renal function also adds to the need for creatinine measurement kits and reagents. For instance, the majority of all occurrences of renal failure are caused, respectively, by diabetes and high blood pressure. An increase in the elderly population worldwide, who are more susceptible to renal problems, favourable government laws designed to promote renal health, and the development of monitoring technology all contribute to the creatinine measurement market growth. Employing point-of-care creatinine measurement equipment as a quick way is one of these potential technical developments.

Growing adoption for enzymatic method

The enzymatic approach converts creatinine to phosphocreatine using the enzyme creatinine phosphokinase (CPK). The measurement of phosphocreatine is then utilized to determine the creatinine concentration. The enzymatic approach may be used in serum, plasma, or whole blood and is quicker than Jaffe's kinetic method. A linear dynamic range of around 30 mg/dL to 700 mg/dL is also seen. The primary drawbacks of the enzymatic approach are its susceptibility to interference with excessive bilirubin, ascorbic acid, and chromogen concentrations in urine samples.

Serum creatinine is anticipated to hold the maximum market share

One of the most used laboratory tests for renal function is serum creatinine. As a measure of kidney function, it is used to calculate the estimated glomerular filtration rate (eGFR). It serves as an excellent indication for identifying chronic renal disorders. The ideal indicator of kidney function, the glomerular filtration rate (GFR), is negatively correlated with the blood creatinine content. GFR is often approximated using equations that take into account endogenous filtration indicators such as serum creatinine (sCr) due to the time-consuming nature of monitoring GFR.

Growing launches and advancements in serum creatinine tests, expanding R&D activity, prominent companies adopting important strategic initiatives, and rising prevalence of chronic renal disease are all driving creatinine measurement market growth.

In North America, it is projected that the preimplantation genetic testing market will grow steadily.

The creatinine measurement market is anticipated to grow during the projected period due to several reasons, including the rising incidence of renal illnesses, the presence of a well-developed healthcare infrastructure, the rising awareness of preventive healthcare, and the acceptance of testing in the area. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases estimates that 37 million individuals in the United States, or almost one-seventh of the population, are affected by chronic kidney disease (CKD). Americans who have diabetes or high blood pressure, the two most common causes of renal disease, are considerably more likely to develop CKD.

Market Key Developments

• In July 2022, Creative Enzymes, one of the top manufacturers of diagnostic enzymes, introduced new enzymes for the manufacture of creatinine test kits.
• In March 2022, The Nova Max Pro Creatinine/eGFR Metre System is now available in all countries that are members of the European Economic Area. Nova Max Pro is a significant new tool for improving renal care through early kidney disease identification and kidney function assessment outside of the hospital.

Segmentation:

By Type

• Jaffe's Kinetic Method
• Enzymatic Method

By Sample Type

• Blood/Serum
• Urine

By End-User

• Hospitals
• Diagnostic Laboratories

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. CREATININE MEASUREMENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Jaffe's Kinetic Method
• 5.3. Enzymatic Method

6. CREATININE MEASUREMENT MARKET, BY SAMPLE TYPE

• 6.1. Introduction
• 6.2. Blood/Serum
• 6.3. Urine

7. CREATININE MEASUREMENT MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Diagnostic Laboratories

8. CREATININE MEASUREMENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Mayo Clinic
• 10.2. Ilex Medical
• 10.3. Biogenix Inc. Pvt. Ltd.
• 10.4. Nova Biomedical
• 10.5. Sigma-Aldrich
• 10.6. Cayman Chemical
• 10.7. Biotec Co.
• 10.8. Fresenius Kidney Care
• 10.9. Fujifilm
• 10.10. Healio